Levetiracetam Solution
Product Images NDC 60687-249

9 FDA label images from American Health Packaging · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 60687-249). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

500 mg/5 mL Levetiracetam Oral Solution Cup Lid (5 mL)

500 mg/5 mL Levetiracetam Oral Solution Cup Lid (5 mL)
Levetiracetam 500 mg/5 mL oral solution label by American Health Packaging. The label includes the proprietary name, dosage form as oral solution USP, strength of 500 mg per 5 mL, and instructions that it delivers 5 mL. It also notes the product is for institutional use only and includes an NDC barcode with the number 60687-249-40. The label indicates this is an Rx-only prescription drug.*
FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Figure 1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Figure 1)
A bar chart comparing the percentage of patients among three groups: Placebo (7.4%, N=95), Levetiracetam 1,000 mg/day (37.1%, N=97), and Levetiracetam 3,000 mg/day (39.6%, N=101). The chart indicates statistically significant differences versus placebo for both Levetiracetam doses.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Figure 2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Figure 2)
Bar chart showing the percentage of patients by treatment group: Placebo (6.3%, N=111), Levetiracetam 1,000 mg/day (20.8%, N=106), and Levetiracetam 2,000 mg/day (35.2%, N=105). Statistical significance versus placebo is indicated for the Levetiracetam groups.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Figure 3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Figure 3)
A bar chart comparing the percentage of patients for placebo and Levetiracetam 3,000 mg/day groups. The Levetiracetam group shows a higher percentage at 39.4%, while the placebo group is at 14.4%. The chart includes a notation indicating the difference is statistically significant versus placebo.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Figure 4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Figure 4)
A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The chart shows approximately 19.6% of patients in the placebo group and about 44.6% in the Levetiracetam group, with a note indicating statistical significance for Levetiracetam versus placebo.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Figure 5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Figure 5)
A bar graph comparing the percentage of patients between placebo and Levetiracetam groups. The y-axis shows the percentage of patients from 0% to 45%. The placebo group (N=51) shows 19.6%, and the Levetiracetam group (N=58) shows 43.1%, with a statistical significance indicator for Levetiracetam versus placebo.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Figure 6)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Figure 6)
A bar graph comparing the percentage of patients in two groups: Placebo (N=84) and Levetiracetam (N=79). The Levetiracetam group shows a higher percentage of patients at 72.2%, marked as statistically significant, compared to 45.2% in the Placebo group.*
FDA Label Image

Levetiracetam Oral Solution Tray Label (Label)

Levetiracetam Oral Solution Tray Label (Label)
Text panel for Levetiracetam Oral Solution USP indicating it is prescription-only and for institutional use only. Instructions direct pharmacists to dispense the accompanying Medication Guide to each patient. Storage conditions specify 20° to 25°C (68° to 77°F), with permitted excursions between 15° to 30°C (59° to 86°F).*
FDA Label Image

Structural Formula (Structure)

Structural Formula (Structure)
Chemical structure of levetiracetam, showing a pyrrolidone ring attached to an ethyl group and an amide group. The structure illustrates the molecular arrangement of the active ingredient levetiracetam.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.